Injectable semaglutide and reductions in HbA1c and weight in the real world in people switched from alternative glucagon‐like peptide‐1 receptor agonists

The ABCD semaglutide audit was designed to capture the routine clinical outcomes of people commenced on semaglutide in the UK. Previous work showed differential reductions in HbA1c and weight dependent on previous glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) exposure. The analysis, in this res...

Descripción completa

Detalles Bibliográficos
Autores principales: Crabtree, Thomas S. J., Adamson, Karen, Reid, Hazel, Barnes, Dennis, Sivappriyan, Siva, Bickerton, Alex, Gallen, Ian W., Field, Benjamin C. T., Idris, Iskandar, Ryder, Robert E. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Research Letters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322019/
https://www.ncbi.nlm.nih.gov/pubmed/35322528
http://dx.doi.org/10.1111/dom.14701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322019/
https://www.ncbi.nlm.nih.gov/pubmed/35322528
http://dx.doi.org/10.1111/dom.14701

Ejemplares similares